🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 11 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 03/08/1993 | 5,00 | 5,38 | 4,88 | 5,38 | +8,86% | 10,00% | 135.000 |
| 02/08/1993 | 4,88 | 5,00 | 4,75 | 4,94 | +1,28% | 5,13% | 67.800 |
| 30/07/1993 | 4,88 | 4,88 | 4,63 | 4,88 | +0,00% | 5,13% | 13.600 |
| 29/07/1993 | 4,63 | 4,88 | 4,56 | 4,88 | +9,86% | 6,76% | 36.200 |
| 28/07/1993 | 4,25 | 4,63 | 4,25 | 4,44 | -1,39% | 8,82% | 53.600 |
| 27/07/1993 | 4,63 | 4,63 | 4,44 | 4,50 | +2,86% | 4,05% | 9.000 |
| 26/07/1993 | 4,25 | 4,63 | 4,25 | 4,38 | -5,41% | 8,82% | 8.400 |
| 23/07/1993 | 4,88 | 5,00 | 4,25 | 4,63 | -2,63% | 15,38% | 124.000 |
| 22/07/1993 | 5,00 | 5,25 | 4,75 | 4,75 | -7,32% | 10,00% | 56.400 |
| 21/07/1993 | 5,00 | 5,13 | 5,00 | 5,13 | -4,65% | 2,50% | 18.000 |
| 20/07/1993 | 5,00 | 5,38 | 5,00 | 5,38 | +7,50% | 7,50% | 8.800 |
| 19/07/1993 | 5,38 | 5,38 | 5,00 | 5,00 | -6,98% | 6,98% | 26.000 |
| 16/07/1993 | 5,25 | 5,38 | 5,00 | 5,38 | -2,27% | 7,14% | 467.800 |
| 15/07/1993 | 5,25 | 5,50 | 5,25 | 5,50 | +1,15% | 4,76% | 25.800 |
| 14/07/1993 | 5,25 | 5,63 | 5,25 | 5,44 | +1,16% | 7,14% | 51.400 |
| 13/07/1993 | 5,25 | 5,38 | 5,25 | 5,38 | +2,38% | 2,38% | 122.400 |
| 12/07/1993 | 5,38 | 5,50 | 5,00 | 5,25 | +5,00% | 9,30% | 54.600 |
| 09/07/1993 | 5,25 | 5,38 | 5,00 | 5,00 | -4,76% | 7,14% | 18.400 |
| 08/07/1993 | 5,00 | 5,25 | 5,00 | 5,25 | +5,00% | 5,00% | 50.400 |
| 07/07/1993 | 4,94 | 5,00 | 4,88 | 5,00 | +0,00% | 2,53% | 28.400 |
| 06/07/1993 | 4,81 | 5,00 | 4,81 | 5,00 | +5,26% | 3,90% | 123.000 |
| 02/07/1993 | 4,75 | 5,00 | 4,75 | 4,75 | +0,00% | 5,26% | 7.600 |
| 01/07/1993 | 4,75 | 5,00 | 4,75 | 4,75 | +0,00% | 5,26% | 43.200 |
| 30/06/1993 | 5,00 | 5,06 | 4,75 | 4,75 | -2,56% | 6,25% | 63.800 |
| 29/06/1993 | 4,88 | 5,13 | 4,88 | 4,88 | -2,50% | 5,13% | 53.400 |
| 28/06/1993 | 5,13 | 5,13 | 4,94 | 5,00 | +2,56% | 3,66% | 94.800 |
| 25/06/1993 | 5,13 | 5,13 | 4,88 | 4,88 | +0,00% | 4,88% | 31.800 |
| 24/06/1993 | 5,25 | 5,25 | 4,88 | 4,88 | -4,88% | 7,14% | 90.800 |
| 23/06/1993 | 5,38 | 5,38 | 5,13 | 5,13 | -4,65% | 4,65% | 19.000 |
| 22/06/1993 | 5,13 | 5,38 | 5,13 | 5,38 | +4,88% | 4,88% | 2.600 |